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Carola A Huber1*, Matthias Schwenkglenks2, Roland Rapold1 and Oliver Reich1
Abstract
Background: Quantifying the burden of diabetes mellitus is fundamental for managing patients in health service
delivery systems and improves the understanding of the importance of prevention and early intervention of
diabetes. In Switzerland, epidemiological data on diabetes are very scarce. In this study we provide a first national
overview of the current situation of diabetes mellitus in Switzerland as well as the development of the prevalence,
incidence, mortality and costs between 2006 and 2011.
Methods: Using health care claims data of a large health insurance group, current epidemiology and costs were
determined from a sample of adult enrollees in 2011. The identification of patients with diabetes was based on
prescription data of diabetes related drugs using the Anatomical Therapeutic Chemical Classification as proxy for
clinical diagnosis. We further evaluated changes in epidemiology and costs between 2006 and 2011. All results
were weighted with census data to achieve an extrapolation to the Swiss general population level.
Results: A total of 920’402 patients were enrolled in 2011 and 49’757 (5.4%) were identified as diabetes cases. The
extrapolated overall prevalence of diabetes in Switzerland was 4.9% (2006, 3.9%). The incidence was 0.58% in 2011
(2007, 0.63%). The extrapolated mortality rate was 2.6% with no significant change over time. Annual diabetes costs
to the mandatory health insurance increased from EUR 5,036 per patient in 2006 to EUR 5’331 per patient in 2011.
Conclusions: This study shows a high medical and economic burden of diabetes. The prevalence and costs of
diabetes in Switzerland increased substantially over time. Findings stress the need for public health strategies to
manage patients with chronic conditions and optimize resource allocation in health service delivery systems.
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Background
The management of patients with diabetes mellitus is a
major challenge for health care systems. The Inter-
national Diabetes Federation (IDF) estimates that about
366 million people suffered from diabetes worldwide in
2011, and the prevalence is expected to rise to 552 mil-
lion by 2030 [1]. Diabetes is often associated with micro-
vascular complications and macrovascular complications
such as heart disease (heart attack, angina pectoris, heart
failure) or hypertension [2,3], and leads to a significant
burden of mortality [4,5]. Due to medical expenditures
attributed to diabetes and its complications, as well as
productivity losses of the patients, the economic cost of
diabetes is immense [6,7]. The American Diabetes Asso-
ciation reported that the total estimated cost of diabetes
was $174 billion in 2007 in the United States [8].
In Switzerland, epidemiological data providing informa-
tion on the burden of diabetes are scarce. There are a few
studies, which used different approaches to estimate the
prevalence [9-11] or the direct costs of diabetes [12,13],
and showed heterogeneous results. Furthermore, they
were based on small study samples, not generalizable to
the Swiss population, or are now outdated. Studies provid-
ing a current and comprehensive overview of the epidemi-
ology and economic burden of diabetes are completely
missing.
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In absence of reliable population-based data on dia-
betes, health care claims data provide a useful basis for
assessing the epidemiology and cost of diabetes. Claims
data are reliable, longitudinal, cover a large population
and are widely used in epidemiological, health services
and outcome research e.g. [14].
The aim of the study was to provide at first a compre-
hensive and up-to-date overview of the Swiss situation.
Using longitudinal data from a large health insurance
population allowed us to assess the current state as well
as potential changes in diabetes prevalence, incidence
and mortality between 6 years. Moreover, we also aimed
to determine the economic burden of diabetes including
the total health care costs from a social insurance payer
perspective.
Methods
Study design and study population
Health insurance is mandatory in Switzerland and the
basic benefit package is the same in the entire country.
The database underlying this study included mandatory
health insurance claims from approximately 1.2 million
persons which lived all over Switzerland and were enrolled
with the Helsana Group, consisting of four health and ac-
cident insurance plans. In a first step, we defined a sample
which included all subjects which were at least 19 years
old in 2011 (2011 sample; n = 1’015’106). These data were
used to give information about the recent epidemiology
and costs of diabetes in Switzerland. In order to addition-
ally identify changes since 2006, we defined a further sam-
ple including all persons aged over 19 years in 2006 (2006
sample; n = 920’402). For prevalence and costs estimates,
both the 2006 and 2011 samples included patients who
were alive and continuously enrolled in the given year. For
mortality estimates, we included all individuals. In order
to determine the incidence of diabetes, we defined in a
next step a retrospective cohort (2006–2011) which in-
cluded adult persons who were continuously enrolled with
Helsana Group during the 6-year period, from January 1,
2006, until December 31, 2011. Subjects who died within
this period were also included. This cohort included
477’870 persons at risk in 2006 and 3’993 persons of those
were new diabetes cases in 2007 (total: n = 491’863). Avail-
able population characteristics included gender, age, lan-
guage area and type of insurance coverage (managed care
model, deductible class). Analyzed data also contained in-
formation on patients’ treatment and its associated health
care cost; they covered all settings of outpatient and in-
patient care and nursing. Since the recorded insurance
claims cover almost all health care invoices, the data
achieve a high degree of completeness.
According to the national ethical and legal regulation,
an ethical approval was not needed. Permission to access
the study data was provided by the Helsana Group.
Identification of patients with diabetes mellitus
In absence of epidemiological data including medical
diagnoses (e.g. International Classification System, ICD),
the WHO Anatomical therapeutic chemical (ATC) [15]
classification system was used to identify patients with
diabetes. Patients were classified as having diabetes when
they were prescribed at least one drug for diabetes
(hypoglycemic medication or insulin; ATC code A10A),
oral blood glucose lowering drug (ATC code A10B) or
other drug used in diabetes (ATC code A10X) anytime
in a given calendar year. Patients with a prescription for
diabetes in a given year were considered as still prevalent
in the following year, irrespective of whether were add-
itional prescriptions. This mapping approach allows a
direct measure of treated diabetes and is frequently used
as a reliable way to identify chronically ill persons in ad-
ministrative data samples [e.g.16]. Based on previous
studies, the use of at least one prescription for diabetes
drugs can be used for an accurate identification of pa-
tients with diabetes across a large population e.g. [17].
Estimation of prevalence, incidence and mortality
Using our diabetes classification, we calculated diabetes
prevalence for the 2006 and 2011 samples. The number
of patients with diabetes was divided by all insured per-
sons in the sample in the same year. Prevalence rates
were stratified by age and sex. Furthermore, we used
census data from the Swiss Federal Office of Statistics to
extrapolate the prevalence of patients with diabetes in
the general adult population for each year. The charac-
teristics of the of the study population and the entire
Swiss population are shown in Table 1. We assumed that
our study sample is approximately representative. How-
ever, the sample included a slightly higher proportion of
elderly persons and the market share of Helsana is not
equally distributed in all 26 Swiss cantons. Therefore we
used the method of extrapolation. We construct various
levels in which the insured persons are represented and
weighted the population by the levels which included the
entire Swiss population (census data).The stratification for
the extrapolation was carried out by age, gender and can-
ton of residence. All 26 Swiss cantons and a total of 16 age
classes, which are based on the classification of the risk
equalization statistics, were taken into account [18].
The annual incidence of diabetes was defined as the
number of newly identified cases with diabetes divided
by the study population which is free of diabetes at the
beginning of the given year. Our calculations excluded
the number of persons with prevalent diabetes in the first
study year. We classified patients as incident cases if they
were identified as persons with diabetes in a given year
and had a minimum diabetes-free period of one year in
the previous years. Incidence estimates were based on the
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cohort data (2006–2011 cohort) and additionally stan-
dardized to the Swiss population using census data.
We included mortality as a further outcome variable. All
deaths of the study sample in 2006 and 2011 were re-
corded but there was no information on cause of death.
Therefore, we calculated the annual all-cause mortality in
patients with diabetes, and additionally extrapolated to the
general Swiss population by census data.
Estimation of costs
The analysis investigating the health care costs of dia-
betes was conducted from the perspective of the Swiss
statutory health insurance system. Annual total health
care costs (Swiss Francs (CHF) exchanged to Euro
(EUR); rate of 0.81) of diabetes patients were obtained
from providers’ claims and defined as the total payments
made by the mandatory health insurance for outpatient
and inpatient services per patient and year. Costs from
the outpatient setting comprised payments for office-
based physician visits, hospital outpatient visits, para-
medical visits, nursing home, medications, laboratory
tests and medical devices. Inpatient costs covered pay-
ments for hospital treatments, hospitalizations, rehabilita-
tion, nursing home and emergency transport services.
Inpatient costs also cover the cost of medications, labora-
tory and medical services during the inpatient episode.
Mean annualized costs of diabetes patients including
standard deviation were calculated for each age and sex
group. Furthermore, we estimated the costs attributable
to diabetes by calculating the difference between the
mean costs per capita/year in patients with diabetes and
the mean cost per capita/year in patients without dia-
betes. Estimations were based on the 2006 and 2011
samples.
Additionally, we used census data to extrapolate the
health care costs of patients with diabetes to the general
adult population for each year.
Estimation of time trends
To determine time trends in epidemiology and costs, we
additionally estimated logistic regression models using
year as a binary variable for comparisons of prevalence,
mortality and costs, based on insured persons in the
2006 and 2011 samples. Year was treated as a continu-
ous variable for determining time trends in incidence in
the 2006–2011 cohort sample. Estimates were reported
as Odds Ratios (OR) including associated 95% confi-
dence interval (95%-CI). All regression models were
controlled for age and sex. Given the skewed nature of
costs, we used a multiple regression model with log-
transformed costs as outcome. Results were given as
exponentiated coefficients with 95%-CI. We reported
p-values <0.05 as significant. All statistical analyses per-
formed using R, version 2.14.2. For performing the ex-
trapolation the R-package “survey” was used.
Results
Our study population included 920’402 subjects com-
prising about 50.000 patients with diabetes mellitus in
2011 (Table 2).
Prevalence
Table 2 shows the overall prevalence of diabetes of 5.4%.
Extrapolated to the adult population of Switzerland, the
overall prevalence of diabetes was 4.9% in 2011. The
number of patients with diabetes increased with age in
both men and women. The extrapolated overall preva-
lence was higher in men than in women [5.7% (CI: 5.6-
6.7) versus 4.2% (CI: 4.1-4.2)] in 2011. However, in the
younger age group (19–39 years), women had a higher
prevalence rate than men [0.8% (CI: 0.7-0.9) vs. 0.6%
(CI: 0.5-0.6)]. In the unadjusted as well as in the extrapo-
lated 2011-sample, all prevalence rates in each sub-
groups (sex/age) showed the same trends, but at a
higher level in the unadjusted sample.
The overall prevalence of diabetes increased from 3.9%
in 2006 to 4.9% in 2011. Moreover, the multivariable
regression model showed a significant increase of the
diabetes prevalence between 2006 and 2011 (OR 1.24,
95%-CI: 1.22-1.26; Table 3).
Incidence
All incidence estimates presented in Table 4 showed simi-
lar trends both in the unadjusted and the extrapolated
Table 1 Characteristics of the study population and the
entire Swiss population
Study population (2011) Entire Swiss population (2011)*
N % N %
Overall
All ages 920402 6’407’133
19-39 282742 30.72 2’215’128 34.57
40-59 315446 34.27 2’369’500 36.98
>59 322214 35.01 1’822’505 28.44
Women
All ages 481616 52.33 3’279’256 51.18
19-39 138936 28.85 1’097’171 33.46
40-59 157528 32.71 1’175’379 35.84
>59 185152 38.44 1’006’706 30.70
Men
All ages 438786 47.67 3’127’877 48.82
19-39 143806 32.77 1’117’957 35.74
40-59 157918 35.99 1’194’121 38.18
>59 137062 31.24 815’799 26.08
*according to the census data of the Swiss Federal Office of Statistic [19].
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sample. The unadjusted overall incidence of diabetes was
0.7%, with a higher rate in men than in women in 2011
(0.9% vs. 0.7%; Table 4). The extrapolated incidence of dia-
betes in 2011 was overall 0.6%, and 0.7% in men and 0.5%
in women. The extrapolated incidence was highest in men
aged over 59 years (1.4%).
Overall, the incidence of diabetes decreased from 0.8%
in 2006 to 0.7% in 2011, representing a relative change
of 12%. The annual relative decrease in incidence was
about 4.0% (OR 0.96, 95% CI: 0.95-0.97; Table 3). Decrease
in incidence was similar in men and in women (change of
11% resp. 12%) and in persons aged >59 years compared
to those aged 40–59 years (change of 18% vs. 15%).
Mortality
Estimations based on the 2006 and 2011 sample were
based on 43’444 and 51’547 patients with diabetes, re-
spectively (Table 5).
The unadjusted annual all-cause mortality in patients
with diabetes in 2011 was 2.9%, and the extrapolated mor-
tality 2.6%, with no significant differences between the
sexes [2.5% (CI: 2.3-2.7) vs. 2.5% (CI: 2.4-2.8), Table 5]. As
with prevalence and incidence, mortality was higher in
older persons than in younger persons in the unadjusted
as well as in the extrapolated sample.
The extrapolated all-cause mortality rate slightly increased
from 2.5% in 2006 to 2.6% in 2011. However, the logistic re-
gression model showed no significant increase in mortality be-
tween 2006 and 2011 (OR 1.07, 95% CI: 0.99-1.16; Table 3).
Costs
As presented in Table 6, annual total health care costs
(Euro (EUR)) of diabetes patients showed similar trends
Table 2 Age- and sex specific prevalence of diabetes in 2006 and 2011
Prevalence
2006 2011
Group No. with
diabetes
Population
without
diabetes
Prevalence
rate (%)
unadjusted
Prevalence rate
(%, 95–CIa)
extrapolatedb
No. with
diabetes
Population
without
diabetes
Prevalence
rate (%)
unadjusted
Prevalence rate
(%, 95–CIa)
extrapolatedb
Differencec
Overall
All ages 41’963 973’143 4.13 3.89 (3.87–3.93) 49’757 870’645 5.41 4.90 (4.86–4.94) 1.01
19–39 1’794 342’167 0.52 0.54 (0.52–0.56) 1’918 280’824 0.68 0.69 (0.65–0.73) 0.15
40–59 9’725 339’452 2.79 2.80 (2.74–2.86) 11’176 304’270 3.54 3.62 (3.54–3.70) 0.82
>59 30’444 291’524 9.46 9.63 (9.53–9.73) 36’663 285’551 11.38 11.68 (11.56–11.80) 2.05
Women
All ages 19’609 513’284 3.68 3.37 (3.33–3.41) 22’724 458’892 4.72 4.15 (4.09–4.21) 0.78
19–39 977 167’320 0.58 0.59 (0.55–0.63) 1’094 137’842 0.79 0.79 (0.73–0.85) 0.20
40–59 3’779 173’579 2.13 2.12 (2.06–2.18) 4’419 153’109 2.81 2.79 (2.71–2.87) 0.67
>59 14’853 172’385 7.93 7.98 (7.86–8.10) 17’211 167’941 9.30 9.41 (9.27–9.55) 1.43
Men
All ages 22’354 459’859 4.64 4.45 (4.39–4.51) 27’033 411’753 6.16 5.68 (5.62–5.74) 1.23
19–39 817 174’847 0.47 0.48 (0.43–0.51) 824 142’982 0.57 0.58 (0.54–0.62) 0.10
40–59 5’946 165’873 3.46 3.48 (3.40–3.56) 6’757 151’161 4.28 4.44 (4.32–4.56) 0.96
>59 15’591 119’139 11.57 11.74 (11.56–11.92) 19’452 117’610 14.19 14.49 (14.29–14.69) 2.75
a95% Confidence Interval.
bPrevalences are extrapolated to the Swiss general population in 2006 and 2011.
cDifference between the extrapolated prevalence rates in 2006 and 2011.
Table 3 Time trend and change in prevalence, incidence,
mortality and costs (2006–2011)
OR (95%-CI)a
Outcomes Logistic regression modelb
Prevalence: 1.24 (1.22-1.26)*
Time change (2006/ 2011)
Incidencec: 0.96 (0.95-0.97)*
Time trend (1-year increase)
Mortalityd: 1.07 (0.99-1.16)
Time change (2006/ 2011)
Exp(coefficient)
Linear regression model
with log-transformed costsb
Costsc: 1.08 (1.06-1.09)*
Time change (2006 to 2011)
aOdds ratio with 95% confidence intervals.
bControlled for age and sex.
cTime trend over the 6-year period 2006–2011.
dAmong persons with diabetes.
*p-value <0.05.
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both in the unadjusted and the extrapolated sample.
Overall, diabetes patients accrued total health care costs
of EUR 8’424 (unadjusted) and EUR 8’239 (extrapolated),
respectively, per patient and year in 2011. Extrapolated
mean costs in women were higher than in men (EUR
8’679 vs. EUR 7’902) and highest in patients aged over
59 years (EUR 8’993).
The extrapolated annual costs attributable to diabetes
(i.e. difference in mean costs between insured persons
with vs. without diabetes) were EUR 5’331 in 2011, with
higher costs in men than in woman (EUR 5’521 vs.
EUR 5’277). The lowest costs were observed in the age
group >59 years, in both sexes.
Overall, the costs attributable to diabetes increased
from EUR 5’036 in 2006 to EUR 5’331 in 2011. Regres-
sion analysis showed a significant increase in costs
among patients with diabetes between 2006 and 2011
(coefficient 1.08, 95% CI: 1.06-1.09; Table 3).
Discussion
This study is the first national study to provide a com-
prehensive overview of the burden of diabetes mellitus
in Switzerland. Based on a large data set, we estimated
the current state as well as the development in diabetes
prevalence, incidence, mortality and cost-of-illness be-
tween 2006 and 2011.
This study yielded an population prevalence of 4.9% in
2011. Our finding is lower than the prevalence rate of
the Swiss CoLaus study (6%) of subjects aged 35–75
years and living in Lausanne in 2003 [9]. However,
prevalence results originating from other studies per-
formed in Switzerland were significantly lower than our
result which might be explained by variations in study
design and definition of diagnosed diabetes. For ex-
ample, Bopp et al. [10] analyzed diagnoses of hospital
discharges and the death registry and reported a diabetes
prevalence of about 3.5-4.3% in 2007/2008. This finding
might be an underestimation, since diabetes is often not
the primary reason for hospitalization and thus not
stated in all medical records. Our estimates of prevalence
and upward time trend are more in line with international
studies reporting higher prevalence levels in the general
population. For example, Wilke et al. [20] reported a stan-
dardized prevalence of 5.5% for patients with Type 2 dia-
betes of all ages in Germany in 2008. Additionally, we
observed a significant increase in diabetes prevalence be-
tween 2006 and 2011. This increasing trend is in line with
estimates from Germany [6] and Canada [5] and from
global estimates of the IDF Atlas (International Diabetes
Federation), which predicted a major increase of 51% in
worldwide cases with diabetes by 2030 [1].
While the diabetes prevalence in the Swiss population
is increasing, our study suggests a decreasing incidence
Table 4 Age- and sex specific incidence of diabetes in 2007 and 2011
Incidence
2007 2011
Group No. with
new
diabetes
Population
at risk
(2006)
Incidence
(%)
unadjusted
Incidence (%,
95% CIa)
extrapolatedb
No. with
new
diabetes
Population
at risk
(2010)
Incidence
(%)
unadjusted
Incidence (%,
95% CIa)
extrapolatedb
Differencec
Overall
All ages 3’993 477’870 0.84 0.63 (0.61–0.65) 3’301 447’390 0.74 0.58 (0.56–0.60) −0.05
19–39 149 88’833 0.17 0.16 (0.13–0.18) 119 85’270 0.14 0.17 (0.14–0.20) 0.01
40–59 1’009 161’989 0.62 0.61 (0.57–0.65) 812 152’714 0.53 0.56 (0.52–0.60) −0.05
>59 2’835 227’048 1.25 1.26 (1.21–1.31) 2’300 223’395 1.03 1.10 (1.05–1.15) −0.16
Women
All ages 1’918 264’173 0.73 0.54 (0.51–0.57) 1’595 246’612 0.65 0.51 (0.48–0.55) −0.03
19–39 96 42’879 0.22 0.20 (0.16–0.25) 96 39’872 0.24 0.25 (0.20–0.30) 0.05
40–59 425 84’330 0.50 0.47 (0.42–0.53) 351 74’740 0.47 0.45 (0.44–0.50) −0.02
>59 1’397 136’964 1.02 1.01 (0.95–1.06) 1’148 132’000 0.87 0.87 (0.82–0.93) −0.14
Men
All ages 2’075 213’697 0.97 0.73 (0.69–0.77) 1’706 200’778 0.85 0.65 (0.61–0.69) −0.08
19–39 53 45’954 0.12 0.11 ()0.08–0.14 39 44’134 0.09 0.09 (0.06–0.12) −0.02
40–59 584 77’659 0.75 0.75 (0.67–0.82) 507 69’311 0.73 0.67 (0.60–0.73) −0.08
>59 1’438 90’084 1.60 1.58 (1.50–1.67) 1’160 87’333 1.33 1.39 (1.30–1.47) −0.19
a95% Confidence Interval.
bIncidences are extrapolated to the Swiss population in 2007 and 2011.
cDifference between the extrapolated incidences 2007 and 2011.
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of treated diabetes over the 6-year time period. The ex-
trapolated incidence of diabetes showed a relative de-
crease by 8% (percentage change from 2007 to 2011).
Previous studies performed in Canada, U.S. and Italy,
examining trends in diabetes incidence provide conflict-
ing results [5,21,22]. Differences in incidence trends of
diabetes might be associated with several risk factors
such as lifestyle habits (i.e. smoking), overweight and en-
vironmental patterns which vary between countries and
cultures. Since obesity as a strong risk factor for diabetes
is rising in Switzerland [23], the observed decrease in
diabetes incidence suggests a meaningful improvement
in other diabetes related risk factors. Previous research
has shown the positive impact of lifestyle interventions
(exercise and/or diet) to reduce the diabetes incidence
and indicates that the effectiveness of the intervention is
independent from weight-changes [24]. However, time-
point incidence rates of most previous studies corrobor-
ate the results of our study, where the estimated diabetes
incidence was 0.5-0.9%.
Our all-cause mortality estimates for diabetes patients
are higher than those found in other studies [5,25,26].
For example, findings from Canada reported a decrease
of 3.3 to 1.6 in all-cause mortality from 1995 to 2005
[5]. However, comparability is limited since considered
time intervals differ from each other.
In this study, we also determined the mean annual dir-
ect medical costs of diabetes. Patients with diabetes
caused health care costs of EUR 8‘239 per year; compari-
son with persons without diabetes lead to a total of EUR
5’331 per patient attributable to diabetes in 2011. Our
cost estimates from 2011 suggest a meaningful increase
in direct costs (excluding nursing home), when compar-
ing with previous national estimates in patients with
type 2 diabetes from 1998/1999 (EUR 2’232) [12]. Com-
parison with international results is difficult as health
systems, medical practice and unit cost differ greatly.
Köster et al. [6] showed that the average health care
costs (including nursing home) of patients with diabetes
in Germany were EUR 5’726 in 2007 and that the costs
attributable to diabetes were EUR 2’605. Another study
calculating the medical costs of diabetes from the U.S.
reported an annual cost (including nursing care) per dia-
betes case of EUR 5’120 in 2007 [27], which is meaning-
ful lower than findings from our study. Additionally, our
results show an increase of the cost attributable to dia-
betes in 2006 to 2011. This finding is in line with inter-
nationally reported data showing an increase of health
Table 5 Age- and sex specific mortality rate in prevalent diabetes cases in 2006 and 2011
Mortality
2006 2011
Group No. of
deathsa
Population
with diabetes
Mortality rate
(%) unadjusted
Mortality rate
(%, 95% CIb)
extrapolatedc
No. of
deathsa
Population
with diabetes
Mortality rate (%)
unadjusted
Mortality rate
(%, 95% CIb)
extrapolatedc
Differenced
Overall
All ages 1’148 43’444 2.64 2.49 (2.35–2.63) 1’481 51’547 2.87 2.56 (2.42–2.70) 0.07
19–39 4 1’862 0.21 0.30 (0.02–0.58) 3 1’993 0.15 0.14 (−0.02–0.30) −0.16
40–59 70 9’995 0.70 0.67 (0.51–0.83) 75 11’424 0.66 0.68 (0.52–0.84) 0.01
>59 1’074 31’587 3.40 3.35 (3.15–3.55) 1’403 38’130 3.68 3.46 (3.28–3.64) 0.11
Women
All ages 525 20’239 2.59 2.50 (2.28–2.72) 670 23’538 2.85 2.53 (2.33–2.73) 0.03
19–39 2 1’011 0.20 0.27 (−0.09–0.63) 2 1’126 0.18 0.16 (−0.06–0.38) −0.11
40–59 23 3’866 0.59 0.60 (0.36–0.84) 21 4’518 0.46 0.49 (0.27–0.71) −0.11
>59 500 15’362 3.25 3.27 (2.99–3.55) 647 17’894 3.62 3.44 (3.30–3.58) 0.17
Men
All ages 623 23’205 2.68 2.49 (2.29–2.69) 811 28’009 2.90 2.57 (2.39–2.75) 0.08
19–39 2 851 0.24 0.34 (−0.12–0.80) 1 867 0.12 0.12 (−0.10–0.34) −0.22
40–59 47 6’129 0.77 0.72 (0.52–0.92) 54 6’906 0.78 0.80 (0.58–1.02) 0.08
>59 574 16’225 3.54 3.41 (3.13–3.69) 756 20’236 3.74 3.48 (3.24–3.72) 0.07
aAmong persons with diabetes.
b95% Confidence Interval.
cMortality rates are extrapolated to the Swiss population in 2006 and 2011.
dDifference between the extrapolated mortality rates 2006 and 2011.
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Table 6 Age- and sex specific mean costs in patients with and without diabetes 2006 and 2011
Costs
2006 2011
Group Patients with diabetes Patients without diabetes Patients with diabetes Patients without diabetes
Mean costs
(EUR)
unadjusted
Mean costs
(EUR)
extrapolateda
Mean costs
(EUR)
unadjusted
Mean costs
(EUR)
extrapolateda
Costs
attributable to
diabetesb
Mean costs
(EUR)
unadjusted
Mean costs
(EUR)
extrapolateda
Mean costs
(EUR)
unadjusted
Mean costs
(EUR)
extrapolateda
Costs
attributable to
diabetesb
Overall
All ages 7489 7495 2564 2459 5036 8424 8239 3157 2907 5331
19–39 6350 6533 1264 1293 5241 6589 6798 1567 1567 5231
40–59 6226 6264 1963 1967 4296 6703 6613 2349 2389 4224
>59 7960 8038 4790 4799 3239 9048 8993 5583 5471 3522
Women
All ages 7916 7957 3008 2882 5075 8837 8679 3699 3402 5277
19–39 6304 6504 1665 1693 4811 6974 7238 2074 2066 5173
40–59 6764 6853 2219 2234 4619 7110 7079 2672 2717 4363
>59 8319 8424 5105 5147 3277 9404 9361 5971 5851 3510
Men
All ages 7116 7121 2069 2003 5118 8078 7902 2553 2381 5521
19–39 6404 6569 880 893 5676 6077 6207 1078 1080 5127
40–59 5885 5909 1697 1700 4209 6437 6325 2023 2061 4265
>59 7622 7701 4332 4334 3367 8732 8697 5030 4973 3724
aMean costs are extrapolated to the Swiss population in 2006 and 2011.
bDifference between the extrapolated mean costs in 2006 and 2011.
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care costs over the past years [28,29]. According to our
results, about 387’100 persons (4.9% of 8 million Swiss
residents) were diagnosed with diabetes and treated in
2011. This implies total health care costs attributable for
diabetes in the compulsory health insurance of CHF 2.5
billion, corresponding to 9.5% of total Swiss statutory
health insurance expenditures in 2011. This finding rep-
resents a significant burden of disease in Switzerland,
and is expected to rise in the future, due to demographic
changes as increasing life expectancy and increasing
number of elderly patients [30]. In addition, with the
current increase in overweight and obesity observed in
Switzerland [23], it stresses the need for public health
strategies to manage patients with diabetes and optimize
resource allocations in health service delivery systems.
The promotion of chronic care management might be
an effective approach to manage and improve health
care for patients with diabetes [31] and adequately pre-
pare for the increasing burden of diabetes on health care
resources. Moreover, our results highlight the import-
ance of prevention and early intervention of diabetes
mellitus, especially in the elderly population. There is a
meaningful impact of age on the occurrence of diabetes
mellitus. The percentage of elderly persons continues to
rise and older people are faced with chronic diseases and
multimorbidity. Previous research has shown that life-
style interventions are very effective in preventing or
delaying the occurrence of chronic diseases such as dia-
betes mellitus [23,32]. Physical activity and healthy diet
helps to prevent diabetes (type 2). Public health efforts
should notably address the prevention of diabetes in the
elderly population and give it a priority in health policy,
decision-making and resource allocation debates.
Several strengths and limitations of our study have to
be taken into account. The main strength is that the
study is based on a very comprehensive health care
claims database which covers a large and geographically
diverse Swiss population and allows for a good and low
cost monitoring of diabetes occurrence. Since we add-
itionally performed an extrapolation of our estimates to
the general adult population, we regard our results as
being representative for the prevalence, incidence, mor-
tality and cost of diabetes for Switzerland. The study also
has several limitations. First, the number of patients with
diabetes may be biased, because clinical diagnoses (e.g.,
ICD-10) were not available. Additionally, our prevalence
might be underestimated. Undiagnosed persons with
diabetes, patients with lifestyle-treatment and patients
with diabetes who were non-adherent to their medica-
tion could not be included in the study. However, diag-
noses based on dispended medications are a valid proxy
for medical diagnoses and widely used in epidemio-
logical and outcomes research to assess prevalence
[14,16]. Second, cost estimates may be slightly too low
as about 3% of the used claims were not paid by the
health insurer but directly by the patient (out-of-pocket).
Third, our cost estimates might be slightly overesti-
mated, since the data do not allow a distinction between
the costs of the treatment of diabetes solely and the
costs of its major comorbidities. Further research is
needed to estimate the costs of diabetes considering the
occurrence of diabetes specific complications such as
cardiovascular diseases. A fourth limitation of this study
is that incidence trend estimations are not completely
representative of the general population, because our co-
hort only included continuously enrolled patients; per-
sons newly insured during the observation period were
not covered. Since we have more or less high fluctua-
tions in our stock of insured persons over the years, we
assumed to have a switching bias in calculating the inci-
dence. However, to define a consistent cohort of persons
and to follow them over several years it is a very com-
mon and frequently used method to determine trends in
diseases. Cohort studies are very important in giving us
a lot of epidemiological information. Using this study
design allows us to see what happens to them with dia-
betes as well as to see who will develop a new disease.
We are able to follow the patients and thus to assess the
incidence and its trend.
Conclusions
In conclusion, this study shows a high medical and eco-
nomic impact of diabetes mellitus. The prevalence and
costs of diabetes in Switzerland increased substantially
between 2006 and 2011. These findings highlight the
need for improvements in prevention and early interven-
tion of diabetes mellitus. Effective strategies should be
developed to manage patients with chronic conditions
and to optimize resource allocations in health service
delivery systems of those with diabetes.
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